NLRP3 and metabolic dysfunction-associated steatotic liver disease: NLRP3 inflammasome activation has also been definitively ascribed as a molecular cause of non-alcoholic fatty liver disease (NAFLD) to non-alcoholic steatohepatitis (NASH) progression—a major and rapidly increasing primary etiology for eventual liver transplant recipients.